Treatment Information

Back

Breast Cancer treatment details. Biologic therapy.

University of Erlangen-Nurnberg, Erlangen, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:3City/State/Province:Erlangen
Treatments:Biologic therapyHospital:University of Erlangen-Nurnberg
Drugs:Journal:Link
Date:Dec 2003

Description:

Patients: This Phase I trial involved 30 women with advanced breast cancer.

Treatment: The treatment consisted of the bispecific antibody MDX-H210 (anti-FcyR1 and anti-HER-2/neu).

Toxicity: Grade 3 toxicities included hepatic, respiratory, and nausea and vomiting. Other toxicities (less than grade 3) included chills, low-grade fever, and hypotension.

Results: No responses were seen and overall survival was not discussed.

Support: Medarex Inc. supported the trial. Medarex produced MDX-H210.

Correspondence: R. Repp, MD




Back